Black Matthew, Gupta Amar, Asrani Sumeet K, Ma Tsung-Wei, Testa Giuliano, Wall Anji
Annette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas.
Proc (Bayl Univ Med Cent). 2022 Mar 9;35(3):273-277. doi: 10.1080/08998280.2022.2034202. eCollection 2022.
While previous research has compared outcomes between living donor liver transplantation (LDLT) and deceased donor liver transplantation, evidence is lacking regarding how donation after circulatory death (DCD) vs donation after brain death (DBD) affects this comparison. Using data from the Scientific Registry of Transplant Recipients for adults listed for liver transplant from 2012 to 2018, we compared 5-year patient and graft survival, readmissions, posttransplant chronic kidney disease (CKD), and return to work for 25,151 patients who underwent LDLT (1223 [4.9%]), DCD-LT (1431 [6.4%]), and DBD-LT (22,497 [89.4%]). LDLT recipients were significantly more likely to have a Model for End-Stage Liver Disease (MELD) score < 15 and to be working prior to transplant ( < 0.001 for both). At 5 years posttransplant, LDLT recipients had significantly more readmissions, but significantly less CKD and better survival than DBD-LT and DCD-LT recipients, as well as significantly better graft survival than DCD-LT recipients ( ≤ 0.01 for all). Significantly more LDLT recipients also returned to work for income ( < 0.01). This study shows a clear advantage of LDLT vs DCD-LT. This information should be weighed in transplantation decisions for patients such as those with low MELD scores who will realistically only be considered for DCD-LT.
虽然先前的研究比较了活体肝移植(LDLT)和尸体肝移植的结果,但关于心脏死亡后捐赠(DCD)与脑死亡后捐赠(DBD)如何影响这种比较的证据却很缺乏。利用2012年至2018年列入肝移植名单的成年受者科学登记处的数据,我们比较了25151例接受LDLT(1223例[4.9%])、DCD-LT(1431例[6.4%])和DBD-LT(22497例[89.4%])患者的5年患者和移植物存活率、再入院情况、移植后慢性肾脏病(CKD)以及恢复工作情况。LDLT受者终末期肝病模型(MELD)评分<15以及移植前仍在工作的可能性显著更高(两者均P<0.001)。移植后5年,LDLT受者的再入院次数显著更多,但与DBD-LT和DCD-LT受者相比,CKD显著更少,存活率更高,并且与DCD-LT受者相比,移植物存活率也显著更高(所有均P≤0.01)。显著更多的LDLT受者也恢复工作以获取收入(P<0.01)。本研究显示了LDLT相对于DCD-LT的明显优势。对于诸如MELD评分低、实际仅会被考虑进行DCD-LT的患者,在移植决策中应权衡这些信息。